ClinicalTrials.gg
RecruitingNCT06423573FOSteRUpdated Sep 28, 2026

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

An observational study in Epidermolysis Bullosa, Dystrophic and Epidermolysis Bullosa, Junctional, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 12 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Sep 28, 2026First sites in Germany and United StatesEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States — 13 open to participants now, 17 under way, 4 of them phase 3. Epidermolysis Bullosa Dystrophica · United States.

Planned enrollment
2nd of 13
170 · median 29
Started
2024
with 2 others
Observational
13 of 46
6 open now
Primary completion
2031-11
later than 15 of 16 live
Registered
38th of 46
by date

Among the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 15 of the 16 other live ones, and was the 38th registered.

Epidermolysis Bullosa Dystrophica

79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.

Browse Epidermolysis Bullosa Dystrophica studies →

Open to participants now

13 of the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, or all of them as a file.
02

Study summary

In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for a minimum of 3 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.

Read the detailed description

Some forms of EB are associated with a greatly increased incidence of aggressive skin and mucosal squamous cell carcinoma (SCC), as well as increased incidence of other skin malignancies including basal cell carcinoma (BCC) and malignant melanoma (MM). This long-term non-interventional study will assess all types of skin malignancies (SCC, BCC, and MM) in DEB and JEB patients. It is an observational study of real-world treatment practices, in which patients will receive standard of care therapy whatever that may entail. Data will be obtained from clinical study centers in the European Union (EU), United Kingdom (UK) and the United States (US). Participants will be followed for a minimum of 3 years, and information about the development and nature of skin malignancies will be collected over this time period both from patients who are taking and those who are not taking Filsuvez.

03

Conditions studied

  • Epidermolysis Bullosa, Dystrophic
  • Epidermolysis Bullosa, Junctional

Keywords

  • Filsuvez
  • Birch bark extract
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with dystrophic EB or junctional EB, whether they are receiving Filsuvez, receiving another treatment for EB, or not receiving any treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of dystrophic EB or junctional EB

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with dystrophic or junctional EB being treated with Filsuvez

    Patients in this cohort will be receiving treatment with Filsuvez for their EB.

    Drug: Filsuvez

  • Patients with dystrophic or junctional EB not being treated with Filsuvez

    Patients in this cohort will be receiving treatment other than Filsuvez or no treatment at all for their EB.

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of first skin malignancy during follow-up in EB patients receiving Filsuvez

    Patients being treated with Filsuvez will be followed for occurrence of skin malignancies from the date of study enrolment until either the date of discontinuation (withdrawal of consent, withdrawal from the site or registry, physician decision, death, or lost to follow-up) or termination of the study

    Time frame: Minimum 3 years

Secondary outcomes

  1. Incidence of first skin malignancy during follow-up in EB patients not receiving Filsuvez

    Patients with EB who are not being treated with Filsuvez will be followed for occurrence of skin malignancies from the date of study enrolment until either the date of discontinuation (withdrawal of consent, withdrawal from the site or registry, physician decision, death, or lost to follow-up) or termination of the study

    Time frame: Minimum 3 years

07

Study locations

6 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Nov 2031, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Dec 18, 2024
Primary completionEst.
Nov 30, 2031
CompletionEst.
Aug 1, 2032
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added — first sites in Germany and United States
Show 7 added (6 United States, 1 Germany)
  • Lucile Packard Children's Hospital · Palo Alto, United States
  • UCHealth / Children's Hospital Colorado · Aurora, United States
  • UF College of Medicine · Gainesville, United States
  • Cincinnati Children's · Cincinnati, United States
  • Childrens Hospital of Philadelphia · Philadelphia, United States
  • Medical University of South Carolina · Charleston, United States
  • UMC Freiburg EB Centre · Freiburg im Breisgau, Germany
Sep 28, 2026
Enrollment
580→170
Sep 28, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameIncidence of first skin malignancy during follow-up in EB patients receiving FilsuvezUp to 5 years → Minimum 3 years
Sep 28, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameIncidence of first skin malignancy during follow-up in EB patients not receiving FilsuvezUp to 5 years → Minimum 3 years
Sep 28, 2026
Sponsor
Amryt Pharma→Chiesi Farmaceutici S.p.A.
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    7 sites added — first sites in Germany and United States
    Show 7 added (6 United States, 1 Germany)
    • Lucile Packard Children's Hospital · Palo Alto, United States
    • UCHealth / Children's Hospital Colorado · Aurora, United States
    • UF College of Medicine · Gainesville, United States
    • Cincinnati Children's · Cincinnati, United States
    • Childrens Hospital of Philadelphia · Philadelphia, United States
    • Medical University of South Carolina · Charleston, United States
    • UMC Freiburg EB Centre · Freiburg im Breisgau, Germany
    Enrollment 580→170
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameIncidence of first skin malignancy during follow-up in EB patients receiving FilsuvezUp to 5 years → Minimum 3 years
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameIncidence of first skin malignancy during follow-up in EB patients not receiving FilsuvezUp to 5 years → Minimum 3 years
    Sponsor Amryt Pharma→Chiesi Farmaceutici S.p.A.
    + 2 other changes: identifiers and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06423573
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Dec 18, 2024
Primary completion
Nov 30, 2031 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Sep 28, 2026

Study contacts

Chiesi Clinical Trials
Contact
clinicaltrials_info@chiesi.com
+3905212791

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion